Alzheimer's disease

Charles River 'reaffirms' commitment to tough neuroscience beat
Charles River 'reaffirms' commitment to tough neuroscience beat
Fierce Biotech
Charles River Laboratories
Neuroscience
Alzheimer's disease
Flag link:
Reeling from a hefty civil and criminal settlement, Avanir stumbles into PhIII Alzheimer's failure
Reeling from a hefty civil and criminal settlement, Avanir stumbles into PhIII Alzheimer's failure
Endpoints
Avanir
Alzheimer's disease
clinical trials
Nuedexta
Flag link:
Research Might Lead to New Alzheimer’s Approaches
Research Might Lead to New Alzheimer’s Approaches
BioSpace
Alzheimer's disease
R&D
Flag link:
BioXcel to trial Apple Watch-drug combination to prevent Alzheimer’s agitation episodes
BioXcel to trial Apple Watch-drug combination to prevent Alzheimer’s agitation episodes
BioSpace
BioXcel
wearables
Apple Watch
Alzheimer's disease
BXCL501
Flag link:
Biogen, Eisai throw out remaining Alzheimer's BACE hope
Biogen, Eisai throw out remaining Alzheimer's BACE hope
Fierce Biotech
Biogen
Eisai
Alzheimer's disease
BACE inhibitors
elenbecestat
aducanumab
Flag link:
Investors lost big as Alzheimer’s R&D went over the cliff in 2019. Will they ever come back?
Investors lost big as Alzheimer’s R&D went over the cliff in 2019. Will they ever come back?
Endpoints
Alzheimer's disease
R&D
Biogen
Neurotrope
Flag link:
Citing phase 2 figures, Axon looks for big pharma investment for Alzheimer’s vaccine
Citing phase 2 figures, Axon looks for big pharma investment for Alzheimer’s vaccine
Pharmaforum
Alzheimer's disease
drug development
vaccines
Axon
Flag link:
New $17M Johns Hopkins research center to study psychedelic drugs in Alzheimer's, addiction and more
New $17M Johns Hopkins research center to study psychedelic drugs in Alzheimer's, addiction and more
Fierce Biotech
psychedelic drugs
Johns Hopkins
drug development
Alzheimer's disease
addiction
Flag link:
D&D bags $137M to fund midphase Alzheimer's, Parkinson's trials
D&D bags $137M to fund midphase Alzheimer's, Parkinson's trials
Fierce Biotech
D&D Pharmatech
neurodegenerative disease
Alzheimer's disease
Parkinson's Disease
Flag link:
Is a Low-Cost Blood Test for Alzheimer's on the Horizon?
Is a Low-Cost Blood Test for Alzheimer's on the Horizon?
BioSpace
diagnostics
Alzheimer's disease
Washington University
Flag link:
Scientists close in on blood test for Alzheimer’s
Scientists close in on blood test for Alzheimer’s
Stat
Alzheimer's disease
dementia
diagnostics
Flag link:
Neon and Neurotrope await signs of proof of concept
Neon and Neurotrope await signs of proof of concept
EP Vantage
Neon Therapeutics
neoantigens
Neurotrope BioScience
Alzheimer's disease
Flag link:
Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs
Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs
Xconomy
Alzheimer's disease
BACE inhibitors
Merck
Eli Lilly
AstraZeneca
Amgen
Novartis
Biogen Eisai
Flag link:
Tiaki hires Bruhn as CEO for Alzheimer's drug discovery push
Tiaki hires Bruhn as CEO for Alzheimer's drug discovery push
Fierce Biotech
Tiaki Therapeutics
Suzanne Bruhn
Alzheimer's disease
Flag link:
Dementia tied to hormone-blocking prostate cancer treatment
Dementia tied to hormone-blocking prostate cancer treatment
Yahoo/AP
Alzheimer's disease
prostate cancer
Flag link:
New Markers For Alzheimer's Disease Could Aid Diagnosis And Speed Up Drug Development
New Markers For Alzheimer's Disease Could Aid Diagnosis And Speed Up Drug Development
NPR
Alzheimer's disease
biomarkers
drug develoment
R&D
diagnostics
Flag link:
Denovo Biopharma Acquires Global Rights to Experimental Alzheimer’s Drug
Denovo Biopharma Acquires Global Rights to Experimental Alzheimer’s Drug
BioSpace
DeNovo
Alzheimer's disease
ORM-12741
Flag link:
Karuna Therapeutics Raises Its IPO Estimate to $85 Million
Karuna Therapeutics Raises Its IPO Estimate to $85 Million
CP Wire
Karuna Therapeutics
IPOs
schizophrenia
Alzheimer's disease
Flag link:
Karuna Therapeutics Raises Its IPO Estimate to $85 Million
Karuna
schizophrenia
Alzheimer's disease
Flag link:
Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
Investors Business Daily
Alzheimer's disease
drug development
Biogen
Eisai
Flag link:

Pages